You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 804 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy

Article metrics

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials in-progress
804 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020136021
Dec 20203604
Jan 20211201
Feb 20213407
Mar 2021114051
Apr 202148019
May 20216049
Jun 20210015
Jul 20210013
Aug 20210022
Sep 20210021
Oct 202164024
Nov 202154023
Dec 20211604
Jan 202288015
Feb 202256012
Mar 202288010
Apr 202266013
May 20224804
Jun 20224008
Jul 20224009
Aug 202246014
Sep 20223006
Oct 202264017
Nov 202292019
Dec 202254015
Jan 20234402
Feb 202340012
Mar 202346010
Apr 20235407
May 202332011
Jun 20231604
Jul 202360021
Aug 202366015
Sep 20234004
Oct 20234005
Nov 202352010
Dec 20237805
Jan 20241401
Feb 202442046
Mar 202494013
Apr 202468010
May 202476010
Jun 202438014
Jul 20244404
Aug 20243804
Sep 20244203
Oct 202443018
Nov 20243209
Dec 20246203
Jan 20253805
Feb 2025603
Mar 20250015
Apr 2025008
May 20250025
Jun 2025103
Total24380716